MSB (ASX) 2024 Here we go again.

Originally posted by dachopper: ↑

Yes Phaedrus, you are correct in that respect.

The same for children also, so we may even find patients are prescribed the cells ( which are anti-inflamatory ), instead of steroids, particularly for patients who have other issues that make steroid use high risk. So that might be 10x if taken straight after steroids for adults, potentially about 20x if taken instead of steroids.

I am sure the steroid non response rate is in the 50% area, but I am assuming here the second line non response rate is 50% of those who never resposponded to the first line... That's my assumption, you would have to find the actual numbers...... but as you mention, at least 10x, maybe 20x the adult market, with children potentially 2x aswell.

As soon as they commence using instead of steroids with positive outcomes... or using as First line standard of care with steroids...... all the other serious indications that use steroids are now on the radar further..... ARDS... SEPSIS..... anything that needs long term anti inflamatory action.

Expand

how about we just tackle the whole gvhd market (chronic and acute) as a prophylactic. a preventative standard of care for all stem cell transplant patients. that would be widespread

December 28, 2023
Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant
An Open-Label Randomized Clinical Trial
Ruihao Huang, MD1; Ting Chen, MD1; Sanbin Wang, MD2; et alJishi Wang, MD3; Yi Su, MD4; Jing Liu, MD5; Yanqi Zhang, PhD6; Xiangyu Ma, PhD7; Qin Wen, MD1; Peiyan Kong, MD1; Cheng Zhang, MD1; Lei Gao, MD1; Jiang F. Zhong, PhD8; Li Gao, MD1; Xi Zhang, MD, PhD1,9
Author Affiliations Article Information
JAMA Oncol. 2024;10(2):220-226. doi:10.1001/jamaoncol.2023.5757
visual abstract iconVisual
Abstract

Key Points
Question Does infusion of mesenchymal stem cells during the early stage after haploidentical hematopoietic stem cell transplant help prevent chronic graft-vs-host disease?

Findings In this randomized clinical trial of 158 patients with acute leukemia, 4 rounds of prophylactic infusion of umbilical cord mesenchymal stem cells during 45 days to 81 days after haploidentical hematopoietic stem cell transplant significantly decreased the incidence and severity of chronic graft-vs-host disease as well as acute graft-vs-host disease. No effect on leukemia relapse or treatment-related adverse events was observed after repeated infusion of mesenchymal stem cells.

Meaning The results of this randomized clinical trial show that repeated mesenchymal stem cells infusion during the early stage after haploidentical hematopoietic stem cell transplant demonstrated clinically meaningful decline in severe chronic graft-vs-host disease occurrence and improvement in graft-vs-host disease-free and relapse-free survival without increasing the incidence of adverse events; however, further research on the MSCs infusion for haploidentical hematopoietic stem cell transplant complications management should be explored